Navigation Links
Control Your siRNA Research

Proven siRNA Controls and Matched Primary Antibodies


Gene Specific siRNA Controls
Whether you are starting out in siRNA research or you are an siRNA expert, you'll appreciate the convenience of the Silencer gene specific siRNA controls. Each Silencer gene specific siRNA control contains 50 g of ready-to-use chemically synthesized and gel purified GAPDH, cyclophilin, c-myc, or -actin siRNA, which is sufficient for 165 transfections (24 well plates). Also included are 25 g of a scrambled Negative Control siRNA and a detailed Instruction Manual. Each control is validated for use in human cell lines and each lot is functionally tested in an siRNA experiment. The GAPDH and cyclophilin siRNAs are also validated for use in mouse cell lines. These siRNA controls are ideal for developing and optimizing siRNA experiments.


Monitoring Transfection Efficiency
Because low transfection efficiency is the most frequent cause of unsuccessful gene silencing experiments, optimizing transfection conditions is critical. The Silencer Gene Specific siRNA Controls are ideal for this application, particularly when they are fluorescently labeled using the simple procedure provided with the Silencer siRNA Labeling Kits. Once transfected into cells, uptake of the labeled siRNA can be correlated to gene silencing by fluorescence microscopy using one of Ambion's new primary antibodies matched to our gene specific siRNA controls (Figure 1).

Figure 1. Characteristi cs of Ambion's Primary Antibodies for siRNA Research.


Primary Antibodies Matched to Silencer Gene Specific Controls
Ambion provides mouse monoclonal antibodies for the detection of GAPDH, c-myc, and -actin by immunofluorescence. Each of these primary antibodies has been used in immunofluorescence experiments at Ambion to detect the reduction in protein levels induced by siRNA. An example of such an experiment is shown in Figure 2. (Antibodies are supplied in solution in a 100 g unit size and are validated for use in immunofluorescence experiments. Note that the concentration and volume will vary by antibody).


Figure 2. Following the Silencing of -actin. An siRNA targeting -actin was labeled with Cy3 using the Silencer siRNA Labeling Kit. The labeled siRNA was transfected into HeLa cells and cells were analyzed 96 hours later. Green: -actin protein detected with anti--actin (Ambion) and a fluorescein labeled secondary antibody. Red: Cy3 labeled siRNA. Blue: DAPI stained nuclei. (Cy3 is a trademark of Amersham Biosciences.)


back to top


Ordering Information
Cat# Product Name Size 1632 Silencer siRNA Labeling Kit - Cy3 65 g labeled siRNA 1634 Silencer siRNA Labeling Kit - FAM 65 g labeled siRNA 4300 anti-GAPDH, mouse monoclonal 6C5 100 g 4302 anti-beta-actin, mouse monoclonal AC-15 100 g
'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Control RT-PCR Primers for Human Gene Transcripts with Varying Abundance
2. Versatile Vectors for Ponasterone A- Inducible Control of Gene Expression in Mammalian Cells
3. Human t-PA Control Primer Set
4. Rapid PCR* Using Active Tube Temperature Control On Thermos PCR Machines
5. Housekeeping Genes: Universal Positive Controls in siRNA Knockdown Experiments
6. Designing Controls for siRNA Experiments
7. RNAi: The Controls You Need
8. RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control
9. Long-Term Instrument Control and Connectivity Solutions
10. Rapamycin Optimized in 100 Liter Fermentor Using BioCommand Control Strategys
11. Custom and library siRNA for efficient gene silencing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/16/2017)... Feb. 16, 2017 UCHealth ( Aurora, ... LungDirect for pulmonary nodule patient management. In addition to ... a spot on the lung, UCHealth looks to improve ... data entry. Stephanie Brown, RN , ... nodule patients with an Excel spreadsheet, which was extremely ...
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... Feb. 16, 2017  Windtree Therapeutics, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... influenza study showed that aerosolized KL4 surfactant reduced ... well-established preclinical animal model. The Company believes that ... of evidence that supports the role of KL4 ...
(Date:2/16/2017)... PHOENIX and NEW YORK ... announced the near completion of their $7M Series B ... on top of the $3.5M led by Mesa Verde ... of 2016.  These resources will be directed towards further ... Test, PCDx, a comprehensive genomic profiling test and expanding ...
Breaking Biology Technology:
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
Breaking Biology News(10 mins):